1. Generics Bulletin
  2. >>Business
  3. >>Deals

Bio-Thera And Biomm Widen Biosimilar Alliance In Brazil

Pair Previously Allied On Chinese Firm’s Proposed Avastin Biosimilar

 
• By Dean Rudge

China’s Bio-Thera Solutions is continuing to pen deals offloading commercialization rights outside of its domestic market to for its BAT2206 biosimilar Stelara (ustekinumab) candidate, this time with Biomm in Brazil.

Donatas Dabravolskas/Alamy Stock Photo
• Source: Shutterstock (Donatas Dabravolskas / Alamy Sto/Alamy Stock Photo)

Bio-Thera Solutions and BIOMM S.A. have expanded their biosimilar commercialization partnership, striking a licensing and supply agreement providing the Brazilian firm with exclusive rights to distribute and market Bio-Thera’s BAT2206 biosimilar Stelara (ustekinumab) candidate in its domestic market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.